Landscape → Metabolic

Dyslipidemia Clinical Trial Landscape

Data updated: May 20, 2026

719 clinical trials tracked since 2008

Dyslipidemia, characterized by abnormal levels of lipids like cholesterol and triglycerides in the blood, is a widespread metabolic condition that significantly elevates the risk of cardiovascular diseases. The clinical trial landscape for dyslipidemia is active, with 714 trials registered since 2008, including 83 currently recruiting, enrolling, or active but not recruiting. The distribution of active trials across phases reveals a substantial presence in Phase 3 (35 trials), alongside similar activity in Phase 1 and Phase 2 (23 trials each), while Phase 4 trials are less common (8 trials). Industry sponsorship is led by Addpharma Inc., which has 7 active trials, followed by Qilu Pharmaceutical Co., Ltd. with 5. Novartis, Arrowhead Pharmaceuticals, and Merck are also prominent sponsors, with 4 and 3 active trials, respectively. The relatively high number of Phase 3 trials suggests a strong focus on late-stage development and potential near-term therapeutic advancements in this area.

87 active

719 total (since 2008)

Phase 1 Active

196 total

Phase 2 Active

167 total

Phase 3 Active

278 total

Phase 4 Active

113 total

Top Industry Sponsors

Sorted by active Active Done Failed

Addpharma Inc. 8 4 0

Qilu Pharmaceutical Co., Ltd. 5 0 0

Novartis 4 15 0

Arrowhead Pharmaceuticals 4 3 0

Merck 3 23 7

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT02262832 ACTIVE NOT RECRUITING

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) n=24

NCT07058077 RECRUITING

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

Merck Sharp & Dohme LLC n=153

NCT07037771 RECRUITING

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

Arrowhead Pharmaceuticals n=60

NCT06712771 ACTIVE NOT RECRUITING

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients

Visirna Therapeutics HK Limited n=46

NCT05682378 RECRUITING

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

Novartis Pharmaceuticals n=195

+ 273 more Phase 3 trials — see full database below

Dyslipidemia — Trials Started by Year (last 10 years)

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Addpharma Inc.

Qilu Pharmaceutical Co., Ltd.

Novartis

Arrowhead Pharmaceuticals

Merck

Beijing Suncadia Pharmaceuticals Co., Ltd

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

JW Pharmaceutical

LIB Therapeutics LLC

AJU Pharm Co., Ltd.

Active Trials by Phase

Phase 1

Phase 2

Phase 3

Phase 4

Enrollment Size Distribution

1-50

203

51-200

297

201-500

133

501-1k

1k+

All Industry Sponsors

Sorted by active Active Done Failed

Addpharma Inc. 8 4 0

Qilu Pharmaceutical Co., Ltd. 5 0 0

Novartis 4 15 0

Arrowhead Pharmaceuticals 4 3 0

Merck 3 23 7

Beijing Suncadia Pharmaceuticals Co., Ltd 3 3 0

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. 3 1 0

JW Pharmaceutical 2 9 0

LIB Therapeutics LLC 2 7 0

AJU Pharm Co., Ltd. 2 1 0

Verve Therapeutics, Inc. 2 1 0

Hasten Biopharmaceutical Co., Ltd. 2 0 0

Regeneron 1 18 1

AstraZeneca 1 14 1

Innovent Biologics (Suzhou) Co. Ltd. 1 6 0

NCT02262832 ACTIVE NOT RECRUITING

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) n=24

NCT07058077 RECRUITING

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

Merck Sharp & Dohme LLC n=153

NCT07037771 RECRUITING

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

Arrowhead Pharmaceuticals n=60

NCT06712771 ACTIVE NOT RECRUITING

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients

Visirna Therapeutics HK Limited n=46

NCT05682378 RECRUITING

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

Novartis Pharmaceuticals n=195

NCT07216482 RECRUITING

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Merck Sharp & Dohme LLC n=975

NCT07473960 RECRUITING

IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia

Innovent Biologics (Suzhou) Co. Ltd. n=198

NCT07421297 RECRUITING

A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. n=760

NCT07473843 NOT YET RECRUITING

Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals n=12

NCT07474649 NOT YET RECRUITING

A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events

Daiichi Sankyo n=103

NCT07465263 NOT YET RECRUITING

A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. n=135

NCT07450378 NOT YET RECRUITING

QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Qilu Pharmaceutical Co., Ltd. n=120

NCT07441317 NOT YET RECRUITING

QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Qilu Pharmaceutical Co., Ltd. n=780

NCT07444086 NOT YET RECRUITING

QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia

Qilu Pharmaceutical Co., Ltd. n=510

NCT06597006 RECRUITING

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Novartis Pharmaceuticals n=9

NCT07421284 NOT YET RECRUITING

A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. n=900

NCT07404553 NOT YET RECRUITING

A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors

Beijing Suncadia Pharmaceuticals Co., Ltd n=126

NCT07230730 RECRUITING

A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

Beijing Suncadia Pharmaceuticals Co., Ltd n=900

NCT05238519 ACTIVE NOT RECRUITING

Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

Essentia Health n=300

NCT06772168 RECRUITING

Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia

CMG Pharmaceutical Co. Ltd n=240

NCT04765657 ACTIVE NOT RECRUITING

Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Novartis Pharmaceuticals n=345

NCT06597019 RECRUITING

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Novartis Pharmaceuticals n=60

NCT06492291 ACTIVE NOT RECRUITING

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

Merck Sharp & Dohme LLC n=3,000

NCT06643130 RECRUITING

Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

JW Pharmaceutical n=162

NCT07102511 NOT YET RECRUITING

Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

LIB Therapeutics LLC n=150

NCT06568471 RECRUITING

A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

Hasten Biopharmaceutical Co., Ltd. n=210

NCT05400317 RECRUITING

A Study to Evaluate the Efficacy and Safety of AD-218

Addpharma Inc. n=520

NCT06747936 NOT YET RECRUITING

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282

Addpharma Inc. n=110

NCT06782646 ENROLLING BY INVITATION

Study on the Sex-specific, Lipid- and Lipoprotein-lowering Effects of Berberine

The University of Hong Kong n=100

NCT06780410 RECRUITING

A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid

Gan & Lee Pharmaceuticals. n=240

NCT06717360 NOT YET RECRUITING

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R

Ahn-Gook Pharmaceuticals Co.,Ltd n=140

NCT04798430 ENROLLING BY INVITATION

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

LIB Therapeutics LLC n=2,000

NCT05621070 RECRUITING

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Shanghai Junshi Bioscience Co., Ltd. n=582

NCT02726555 RECRUITING

The Efficacy and Safety of Combined Therapy With Red Yeast Rice and Low-dose Statin：Comparing With Standardized Statin

Wenzhou Medical University n=240

NCT06220266 RECRUITING

Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal Women

Dhurakij Pundit University n=10

NCT07564726 COMPLETED

Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol

Celltrion Pharm, Inc. n=163

NCT06450366 COMPLETED

A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

Merck Sharp & Dohme LLC n=301

NCT07444762 COMPLETED

Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A

Daewon Pharmaceutical Co., Ltd. n=184

NCT05952869 COMPLETED

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

Merck Sharp & Dohme LLC n=303

NCT04652726 COMPLETED

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

Novartis Pharmaceuticals n=141

NCT04659863 COMPLETED

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

Novartis Pharmaceuticals n=13

NCT05888103 COMPLETED

Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.

Novartis Pharmaceuticals n=207

NCT06723652 COMPLETED

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Beijing Suncadia Pharmaceuticals Co., Ltd n=55

NCT05923281 COMPLETED

A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance

Kowa Company, Ltd. n=71

NCT03527069 COMPLETED

Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment

EMS n=146

NCT07253584 COMPLETED

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia

Shenzhen Salubris Pharmaceuticals Co., Ltd. n=720

NCT06165250 COMPLETED

A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C

Boryung Pharmaceutical Co., Ltd n=156

NCT05763875 COMPLETED

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

Novartis Pharmaceuticals n=350

NCT06005597 COMPLETED

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

NewAmsterdam Pharma n=407

NCT03071692 TERMINATED

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Kowa Research Institute, Inc. n=10,544

NCT04669041 COMPLETED

A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy

Sanofi n=305

NCT05142722 COMPLETED

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

NewAmsterdam Pharma n=2,530

NCT05952856 COMPLETED

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

Merck Sharp & Dohme LLC n=2,912

NCT06955104 COMPLETED

Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia

JW Pharmaceutical n=145

NCT05425745 COMPLETED

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

NewAmsterdam Pharma n=354

NCT04998981 COMPLETED

A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C

Kowa Company, Ltd. n=353

NCT03409744 COMPLETED

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Regeneron Pharmaceuticals n=116

NCT05611528 COMPLETED

Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia

Daniel Gaudet n=10

NCT05260411 COMPLETED

A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

Akeso n=246

NCT05255094 COMPLETED

A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Akeso n=464

NCT05255458 COMPLETED

A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Akeso n=122

NCT00152698 WITHDRAWN

Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia

University of Erlangen-Nürnberg Medical School

NCT04709536 COMPLETED

A Study of IBI306 in Participants With Hypercholesterolemia

Innovent Biologics (Suzhou) Co. Ltd. n=306

NCT04964544 COMPLETED

Technology-Assisted Cholesterol Trial in Consumers (TACTiC)

AstraZeneca n=1,196

NCT05004675 COMPLETED

Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients

LIB Therapeutics LLC n=166

NCT05930028 COMPLETED

A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

Boryung Pharmaceutical Co., Ltd n=148

NCT03689946 COMPLETED

Effect of Evolocumab on Coronary Atherosclerosis

Cedars-Sinai Medical Center n=55

NCT04233918 COMPLETED

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Regeneron Pharmaceuticals n=20

NCT02956590 COMPLETED

Dyslipidemia of Obesity Intervention in Teens

Carelon Research n=122

NCT06448962 COMPLETED

Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

Addpharma Inc. n=109

NCT02624869 COMPLETED

Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)

Amgen n=163

NCT03080935 TERMINATED

Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

Amgen n=1,600

NCT01764633 COMPLETED

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Amgen n=27,564

NCT01624142 COMPLETED

Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

Amgen n=300

NCT01274559 TERMINATED

Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

Merck Sharp & Dohme LLC n=1,173

NCT00867165 COMPLETED

Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)

Organon and Co n=138

NCT00782184 COMPLETED

Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)

Organon and Co n=250

NCT03768427 COMPLETED

Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)

Organon and Co n=454

NCT02741245 COMPLETED

A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)

Organon and Co n=321

NCT02550288 COMPLETED

A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)

Organon and Co n=309

NCT02748057 COMPLETED

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)

Organon and Co n=135

NCT02460159 COMPLETED

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)

Organon and Co n=135

NCT00783263 COMPLETED

A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)

Organon and Co n=440

NCT05325203 COMPLETED

A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

Shanghai Junshi Bioscience Co., Ltd. n=135

NCT05331014 COMPLETED

To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension

JW Pharmaceutical n=155

NCT03814187 COMPLETED

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

Novartis Pharmaceuticals n=3,275

NCT04885218 COMPLETED

Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia

Jiangsu HengRui Medicine Co., Ltd. n=692

NCT04797104 COMPLETED

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction

LIB Therapeutics LLC n=478

NCT04289649 COMPLETED

K-924 Phase III Confirmatory Study

Kowa Company, Ltd. n=293

NCT04289662 COMPLETED

K-924 Phase III Long Term Study

Kowa Company, Ltd. n=110

NCT04179669 COMPLETED

Safety and Efficacy of IBI306 in HeFH Patients

Innovent Biologics (Suzhou) Co. Ltd. n=149

NCT04031742 COMPLETED

A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia

Innovent Biologics (Suzhou) Co. Ltd. n=18

NCT05970679 COMPLETED

Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A

Daewon Pharmaceutical Co., Ltd. n=252

NCT01710007 COMPLETED

Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia

Orient Pharma Co., Ltd. n=202

NCT02947620 COMPLETED

Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)

Daewoong Pharmaceutical Co. LTD. n=185

NCT04849000 COMPLETED

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

Jiangsu HengRui Medicine Co., Ltd. n=709

NCT04844125 COMPLETED

SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research

Jiangsu HengRui Medicine Co., Ltd. n=144

NCT02867813 COMPLETED

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

Amgen n=5,035

NCT04790513 COMPLETED

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

LIB Therapeutics LLC n=204

NCT04034485 COMPLETED

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

LIB Therapeutics LLC n=65

NCT03433755 TERMINATED

Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia

Amgen n=259

NCT02548832 COMPLETED

Bezafibrate Plus Berberine in Mixed Dyslipidemia

University of Guadalajara n=36

NCT05742022 COMPLETED

"Phospholipovit" vs Placebo in Patients With Combined Hyperlipidemia

Institute of Biomedical Chemistry, Russia n=100

NCT03851705 COMPLETED

A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Novartis Pharmaceuticals n=56

NCT02585895 COMPLETED

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

Amgen n=39

NCT01879319 COMPLETED

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

Amgen n=164

NCT01763866 COMPLETED

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Amgen n=2,067

NCT01763827 COMPLETED

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Amgen n=615

NCT02392559 COMPLETED

Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

Amgen n=158

NCT02729025 COMPLETED

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))

Amgen n=129

NCT01516879 COMPLETED

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

Amgen n=905

NCT02833844 COMPLETED

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

Amgen n=467

NCT05131997 COMPLETED

A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A

Addpharma Inc. n=290

NCT05234775 COMPLETED

Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product

LIB Therapeutics LLC n=22

NCT04643093 COMPLETED

Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Orient Pharma Co., Ltd. n=390

NCT04289285 COMPLETED

Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

Innovent Biologics (Suzhou) Co. Ltd. n=804

NCT02476006 COMPLETED

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

Sanofi n=998

NCT01154036 COMPLETED

MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)

Organon and Co n=1,547

NCT01370603 COMPLETED

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)

Organon and Co n=328

NCT01370590 COMPLETED

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)

Organon and Co n=406

NCT04584736 COMPLETED

To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia

JW Pharmaceutical n=283

NCT04312698 COMPLETED

Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

Chong Kun Dang Pharmaceutical n=100

NCT03156621 COMPLETED

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Regeneron Pharmaceuticals n=69

NCT03399786 COMPLETED

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Regeneron Pharmaceuticals n=65

NCT04158076 COMPLETED

Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine

Addpharma Inc. n=131

NCT02670434 WITHDRAWN

Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia

Kowa Research Institute, Inc.

NCT02799758 WITHDRAWN

Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia

Kowa Research Institute, Inc.

NCT04652349 COMPLETED

Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia

Hanmi Pharmaceutical Company Limited n=279

NCT03067441 COMPLETED

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

Esperion Therapeutics, Inc. n=1,462

NCT02662894 WITHDRAWN

Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.

EMS

NCT01964326 COMPLETED

Actual Use Trial of Atorvastatin Calcium 10 mg

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. n=1,311

NCT00827606 COMPLETED

Atorvastatin Three Year Pediatric Study

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. n=272

NCT03872232 COMPLETED

Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan

Addpharma Inc. n=180

NCT03510715 COMPLETED

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Sanofi n=18

NCT02634580 COMPLETED

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4

Amgen n=61

NCT03397121 COMPLETED

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

The Medicines Company n=482

NCT01763905 COMPLETED

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

Amgen n=307

NCT01709513 COMPLETED

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

Regeneron Pharmaceuticals n=314

NCT01860729 COMPLETED

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

Merck Sharp & Dohme LLC n=589

NCT03001076 COMPLETED

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

Esperion Therapeutics, Inc. n=269

NCT02666664 COMPLETED

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

Esperion Therapeutics, Inc. n=2,230

NCT02326220 COMPLETED

Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy

Regeneron Pharmaceuticals n=62

NCT02991118 COMPLETED

Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

Esperion Therapeutics, Inc. n=779

NCT01730053 COMPLETED

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

Regeneron Pharmaceuticals n=305

NCT02988115 COMPLETED

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

Esperion Therapeutics, Inc. n=345

NCT01420549 COMPLETED

Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia

Ache Laboratorios Farmaceuticos S.A. n=129

NCT01524289 COMPLETED

Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

Merck Sharp & Dohme LLC n=306

NCT02227784 TERMINATED

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

Eli Lilly and Company n=366

NCT02715726 COMPLETED

Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia

Sanofi n=615

NCT00965055 TERMINATED

Ezetimibe in Patients Hypo-responsive to Statins

University of California, San Diego n=2

NCT03583905 COMPLETED

Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet

Chong Kun Dang Pharmaceutical n=154

NCT02455336 COMPLETED

Fenofibrate Treatment in SCI

VA Office of Research and Development n=23

NCT01236365 COMPLETED

Statins in Children With Type 1 Diabetes and Hypercholesterolemia

Nemours Children's Clinic n=42

NCT02524106 TERMINATED

Bococizumab HIV Evaluation (B-HIVE) Study

University of California, San Francisco n=11

NCT01763918 COMPLETED

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

Amgen n=331

NCT01854918 COMPLETED

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

Amgen n=3,681

NCT03156842 COMPLETED

Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia

Boryung Pharmaceutical Co., Ltd n=138

NCT01813006 COMPLETED

Effect of Omega-3 Fatty Acid on Endothelial Function

Nordlandssykehuset HF n=34

NCT01475825 COMPLETED

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

Kastle Therapeutics, LLC n=309

NCT02304484 COMPLETED

Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Amgen n=770

NCT01813422 COMPLETED

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

Amgen n=970

NCT02634606 TERMINATED

Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood

University of California, Los Angeles n=13

NCT01335997 TERMINATED

Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)

Merck Sharp & Dohme LLC n=1,139

NCT02584504 COMPLETED

Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin

Sanofi n=163

NCT03067688 COMPLETED

Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia

Yuhan Corporation n=202

NCT02662569 COMPLETED

Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia

Amgen n=986

NCT01849497 COMPLETED

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Amgen n=149

NCT01588496 COMPLETED

Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities

Amgen n=58

NCT01984424 COMPLETED

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

Amgen n=511

NCT03433196 COMPLETED

Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases

Zhejiang Hisun Pharmaceutical Co. Ltd. n=255

NCT03413462 COMPLETED

Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia

Zhejiang Hisun Pharmaceutical Co. Ltd. n=374

NCT02173158 COMPLETED

Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy

Aegerion Pharmaceuticals, Inc. n=9

NCT02260635 TERMINATED

A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia

Eli Lilly and Company n=54

NCT02260648 TERMINATED

A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia

Eli Lilly and Company n=149

NCT02189837 COMPLETED

Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody

Amgen n=89

NCT02586129 COMPLETED

Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes

Yuhan Corporation n=249

NCT02166593 COMPLETED

Clinical Trial to Evaluate the Efficacy and Safety of Pravafenix Cap to Verify the Superiority Than Atorvastatin

Yooyoung Pharmaceutical Co., Ltd. n=302

NCT03103256 COMPLETED

Clinical Trial to Evaluate the Efficacy and Safety of YHP1701

Yuhan Corporation n=106

NCT02739984 COMPLETED

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia

Amgen n=424

NCT01294683 TERMINATED

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Merck Sharp & Dohme LLC n=977

NCT03571087 COMPLETED

Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia

Hanlim Pharm. Co., Ltd. n=374

NCT03618797 COMPLETED

A Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin/Fenofibrate in Complex-dyslipidemia

Hanlim Pharm. Co., Ltd. n=347

NCT02100514 COMPLETED

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Pfizer n=746

NCT01968967 COMPLETED

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Pfizer n=2,139

NCT02023879 COMPLETED

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Sanofi n=233

NCT01954394 COMPLETED

Open Label Study of Long Term Safety Evaluation of Alirocumab

Sanofi n=986

NCT02827903 COMPLETED

Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia

Jeil Pharmaceutical Co., Ltd. n=237

NCT03088254 COMPLETED

Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin

Jeil Pharmaceutical Co., Ltd. n=126

NCT00616772 COMPLETED

Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood

AbbVie (prior sponsor, Abbott) n=682

NCT03566316 COMPLETED

Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia

IlDong Pharmaceutical Co Ltd n=134

NCT02749994 COMPLETED

A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)

IlDong Pharmaceutical Co Ltd n=396

NCT00943306 COMPLETED

Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia

Aegerion Pharmaceuticals, Inc. n=19

NCT03536598 COMPLETED

Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia

HK inno.N Corporation n=203

NCT00787306 COMPLETED

Cardiovascular Health And Risk Modification in Family Health Teams

University of Toronto n=229

NCT02434497 COMPLETED

A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia

AstraZeneca n=9

NCT02765841 WITHDRAWN

Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy

Aegerion Pharmaceuticals, Inc.

NCT03429998 COMPLETED

Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia

Hospital General Universitario Gregorio Marañon n=9

NCT03210532 COMPLETED

Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia

Daewon Pharmaceutical Co., Ltd. n=129

NCT02207634 COMPLETED

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects

Amgen n=1,974

NCT01267227 COMPLETED

Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress

University of Mississippi Medical Center n=80

NCT02458287 COMPLETED

Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia

Pfizer n=299

NCT02135029 COMPLETED

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

Pfizer n=184

NCT02947334 WITHDRAWN

Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects

Pfizer

NCT03288038 COMPLETED

The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia

Shin Poong Pharmaceutical Co. Ltd. n=382

NCT00955903 COMPLETED

Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults

University of Alabama at Birmingham n=167

NCT02289963 COMPLETED

Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

Sanofi n=199

NCT01968980 COMPLETED

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia

Pfizer n=370

NCT02407548 COMPLETED

The Effects of Dietary Supplement of Coenzyme Q10（CoQ10） on Dyslipidemia

Sun Yat-sen University n=150

NCT02955368 WITHDRAWN

Clinical Trial to Evaluate the Efficacy and Safety of DP-R212

Alvogen Korea

NCT01760460 COMPLETED

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)

Merck Sharp & Dohme LLC n=307

NCT01968954 COMPLETED

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Pfizer n=711

NCT03141827 COMPLETED

The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production

University Health Network, Toronto n=9

NCT01717300 COMPLETED

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)

Merck Sharp & Dohme LLC n=459

NCT01926782 COMPLETED

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

Regeneron Pharmaceuticals n=803

NCT01600703 COMPLETED

Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans

University Health Network, Toronto n=21

NCT02899455 COMPLETED

Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia

Hanmi Pharmaceutical Company Limited n=146

NCT02126358 COMPLETED

Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)

LG Life Sciences n=290

NCT02390375 COMPLETED

Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia

Daewon Pharmaceutical Co., Ltd. n=348

NCT02107898 COMPLETED

Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)

Sanofi n=216

NCT00694109 COMPLETED

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Kastle Therapeutics, LLC n=144

NCT00706849 COMPLETED

Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease

Kastle Therapeutics, LLC n=124

NCT00770146 COMPLETED

Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

Kastle Therapeutics, LLC n=158

NCT00794664 COMPLETED

Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis

Kastle Therapeutics, LLC n=58

NCT01644188 COMPLETED

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

Sanofi n=720

NCT02226198 COMPLETED

A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia

AstraZeneca n=20

NCT00718965 TERMINATED

Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia

Sanofi n=826

NCT00766688 TERMINATED

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia

Sanofi n=643

NCT00729027 TERMINATED

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia

Sanofi n=1,015

NCT00741715 TERMINATED

Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia

Sanofi n=1,736

NCT01824238 COMPLETED

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)

Merck Sharp & Dohme LLC n=68

NCT01228032 COMPLETED

The Health Outcomes Management and Evaluation (HOME) Study

Emory University n=447

NCT01623115 COMPLETED

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Sanofi n=486

NCT02451098 COMPLETED

Clinical Trial to Evaluate the Efficacy and Safety of CKD-391

Chong Kun Dang Pharmaceutical n=385

NCT02609295 COMPLETED

Effects of α-linolenic Acid Supplementation on Hemostasis in Nondiabetic and Hypercholesterolemic Subjects

Yonsei University n=86

NCT01953328 COMPLETED

Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk

Amgen n=409

NCT01507831 COMPLETED

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Sanofi n=2,341

NCT01644474 COMPLETED

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia

Sanofi n=103

NCT01644175 COMPLETED

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

Sanofi n=316

NCT01709500 COMPLETED

Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)

Regeneron Pharmaceuticals n=249

NCT01541943 COMPLETED

Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia

HanAll BioPharma Co., Ltd. n=356

NCT02205606 COMPLETED

Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia

Hanmi Pharmaceutical Company Limited n=412

NCT01598948 COMPLETED

Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis

Ludwig-Maximilians - University of Munich n=17

NCT01730040 COMPLETED

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

Regeneron Pharmaceuticals n=355

NCT01841684 TERMINATED

Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)

Merck Sharp & Dohme LLC n=2

NCT02445352 COMPLETED

Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia

Alvogen Korea n=379

NCT02187757 COMPLETED

Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels

PreEmptive Meds, Pvt. Ltd n=180

NCT01414166 TERMINATED

Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)

Merck Sharp & Dohme LLC n=244

NCT00664287 WITHDRAWN

Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

Merck Sharp & Dohme LLC

NCT01958775 COMPLETED

Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2

University Health Network, Toronto n=12

NCT00961636 COMPLETED

A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)

Merck Sharp & Dohme LLC n=1,152

NCT01918332 COMPLETED

Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia

LG Life Sciences n=168

NCT01674712 COMPLETED

A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease

Abbott n=575

NCT00887653 COMPLETED

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

The Miriam Hospital n=20

NCT01914432 COMPLETED

Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia

Yuhan Corporation n=210

NCT01402843 COMPLETED

Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia

JW Pharmaceutical n=150

NCT02116517 COMPLETED

Effects of Green Tea Extract on Obese Women With High Level of LDL

National Yang Ming Chiao Tung University n=73

NCT02091024 COMPLETED

Blood Lipid-lowering Effect of Brown Alga Ecklonia Cava

Chonbuk National University Hospital n=80

NCT02005900 COMPLETED

Effect of DHA on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in HIV Patients Under HAART.

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau n=66

NCT01007344 COMPLETED

Flaxseed Compared With Placebo in Patients With Hypercholesterolemia

The Hospital for Sick Children n=30

NCT01764295 COMPLETED

Clinical Study for Patients With Hypertension Associated With Dyslipidemia

Daewoong Pharmaceutical Co. LTD. n=150

NCT01442987 COMPLETED

Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

Hanmi Pharmaceutical Company Limited n=230

NCT01326442 COMPLETED

Vitamin D and Omega-3 Inhibit Metabolic Syndrome

University of Guelph n=40

NCT01349010 COMPLETED

Efficacy and Safety of Imported Probucol to Treat Hyperlipidemia

Otsuka Beijing Research Institute n=264

NCT01865370 COMPLETED

Efficacy and Safety of Kochujang Pills on Blood Lipids Profiles in Hyperlipidemia Subjects

Chonbuk National University Hospital n=30

NCT01360567 COMPLETED

The Effect of Green Tea Extract on Type 2 Diabetes With Hyperlipidemia

Taipei City Hospital n=102

NCT01562080 COMPLETED

Combined Effects of Bioactive Compounds in Lipid Profile

Rottapharm Spain n=118

NCT01402128 COMPLETED

Efficacy and Safety of Fermented Barley on Decrement of Body Fat in Obese Subjects

Chonbuk National University Hospital n=80

NCT01402102 COMPLETED

A Human Trial to Evaluate the Efficacy and Safety of Aged Garlic Powder on Improvement of Blood Lipids in Subjects With Hyperlipidemia

Chonbuk National University Hospital n=60

NCT00812955 COMPLETED

Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides

AstraZeneca n=474

NCT00680017 COMPLETED

30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

AstraZeneca n=280

NCT00826774 COMPLETED

Improving the Management of Obesity in Primary Care Practice (The Power-UP Trial)

University of Pennsylvania n=390

NCT00683618 COMPLETED

Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia

AstraZeneca n=934

NCT00897975 COMPLETED

Red Yeast Rice and Phytosterols In Statin Intolerance

Chestnut Hill Health System n=200

NCT00639158 COMPLETED

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

Abbott n=543

NCT00854503 COMPLETED

Metabolic and Vascular Effects of Statins in Untreated Dyslipidemic Diabetic Patients

University of Rome Tor Vergata n=30

NCT00630877 COMPLETED

Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin

Abbott n=276

NCT00626392 COMPLETED

Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia

Abbott n=277

NCT00713167 COMPLETED

The Efficacy of Red Grape Seed Extract on Lipid Profile and Oxidized Low-Density Lipoprotein (OX-LDL)

Shahid Beheshti University of Medical Sciences n=55

NCT02262806 ACTIVE NOT RECRUITING

Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT04941599 RECRUITING

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

Vanderbilt University Medical Center

NCT07447206 NOT YET RECRUITING

Vascular Intervention Strategies Trial for Alzheimer's

University of Southern California

NCT07489209 RECRUITING

A Dose-exploration Study of EDP167 in HoFH

Eddingpharm (Zhuhai) Co., Ltd.

NCT07477704 NOT YET RECRUITING

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

Regeneron Pharmaceuticals

NCT06488105 RECRUITING

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial

Wake Forest University Health Sciences

NCT07391722 NOT YET RECRUITING

DNV001 Injection in Patients With Hypercholesterolemia

Hangzhou Dinovate Biotech Co., Ltd

NCT06497127 ACTIVE NOT RECRUITING

A Study in Patients With Mixed Dyslipidemia

Shanghai Argo Biopharmaceutical Co., Ltd.

NCT07223658 RECRUITING

Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia

Arrowhead Pharmaceuticals

NCT07229937 RECRUITING

A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia

Shandong Suncadia Medicine Co., Ltd.

NCT06822946 RECRUITING

Zhibitai Capsules for the Treatment of Primary Hyperlipidemia

Chengdu Diao Jiuhong Pharmaceutical Factory

NCT05217667 ACTIVE NOT RECRUITING

Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

Arrowhead Pharmaceuticals

NCT06369571 ENROLLING BY INVITATION

Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet

Johns Hopkins University

NCT07100418 RECRUITING

A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia

Fujian Shengdi Pharmaceutical Co., Ltd.

NCT07133815 NOT YET RECRUITING

Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Beijing Suncadia Pharmaceuticals Co., Ltd

NCT06750341 NOT YET RECRUITING

Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol

Qilu Pharmaceutical Co., Ltd.

NCT06700408 NOT YET RECRUITING

RCT for the Chinese Medicine in Treating Hypercholesterolemia

Chinese University of Hong Kong

NCT06503172 RECRUITING

Whole Grain Job's Tear, Muscle Health, Blood Glucose and Lipid Level

Taipei Veterans General Hospital, Taiwan

NCT06422650 RECRUITING

Effect of Nigella Sativa in Atorvastatin Treated Hyperlipidaemia

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

NCT07592858 NOT YET RECRUITING

Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study

University of Rhode Island

NCT04998201 COMPLETED

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

Arrowhead Pharmaceuticals

NCT07421232 COMPLETED

A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

NCT06471218 COMPLETED

Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

Beijing Suncadia Pharmaceuticals Co., Ltd

NCT03038022 COMPLETED

Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Madrigal Pharmaceuticals, Inc.

NCT07278830 COMPLETED

A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia

Shenzhen Salubris Pharmaceuticals Co., Ltd.

NCT04832971 COMPLETED

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

Arrowhead Pharmaceuticals

NCT06173570 COMPLETED

A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia

AstraZeneca

NCT06009393 COMPLETED

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Beijing Suncadia Pharmaceuticals Co., Ltd

NCT05694260 COMPLETED

A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

Esperion Therapeutics, Inc.

NCT04164888 COMPLETED

Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy

Civi Biopharma, Inc.

NCT04823611 COMPLETED

A Study of AZD8233 in Participants With Dyslipidemia.

AstraZeneca

NCT05261126 COMPLETED

A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

Merck Sharp & Dohme LLC

NCT05421078 COMPLETED

A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.

NewAmsterdam Pharma

NCT04753606 COMPLETED

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

NewAmsterdam Pharma

NCT05266586 COMPLETED

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

NewAmsterdam Pharma

NCT04666298 COMPLETED

Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C

Novartis Pharmaceuticals

NCT04784442 COMPLETED

A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia

Otsuka Pharmaceutical Co., Ltd.

NCT04770389 COMPLETED

Randomized Study of Obicetrapib in Combination With Ezetimibe

NewAmsterdam Pharma

NCT05795517 COMPLETED

Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD）

Haisco Pharmaceutical Group Co., Ltd.

NCT01069783 COMPLETED

Study of A3309 in Patients With Dyslipidemia

Albireo

NCT04447820 COMPLETED

Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR

Kowa Research Institute, Inc.

NCT00810979 COMPLETED

Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia

Response Pharmaceuticals

NCT03815812 COMPLETED

Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia

Innovent Biologics (Suzhou) Co. Ltd.

NCT02651675 TERMINATED

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

REGENXBIO Inc.

NCT04846231 COMPLETED

Supplements, Placebo, or Rosuvastatin Study

The Cleveland Clinic

NCT02178098 COMPLETED

Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

Esperion Therapeutics, Inc.

NCT03060577 COMPLETED

An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

Novartis Pharmaceuticals

NCT02681055 COMPLETED

Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

MediciNova

NCT03381287 COMPLETED

A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia

HighTide Biopharma Pty Ltd

NCT04173403 COMPLETED

A Long-term Study of AK102 in Patients With Hypercholesterolemia

Akeso

NCT04358432 COMPLETED

A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia

Akeso

NCT03933293 COMPLETED

A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH

Akeso

NCT04173793 COMPLETED

A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Akeso

NCT03175367 COMPLETED

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Regeneron Pharmaceuticals

NCT03944109 COMPLETED

The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia

Jiangsu HengRui Medicine Co., Ltd.

NCT01380730 COMPLETED

LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

Amgen

NCT01375751 COMPLETED

Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study

Amgen

NCT01375777 COMPLETED

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

Amgen

NCT01375764 COMPLETED

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects

Amgen

NCT00768274 COMPLETED

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

Resverlogix Corp

NCT01439880 COMPLETED

Open Label Study of Long Term Evaluation Against LDL-C Trial

Amgen

NCT03611010 COMPLETED

Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients

Cumberland Pharmaceuticals

NCT04573218 COMPLETED

Supplementation of Oil Palm Phenolics to Improve Lipid Profile in Subjects With Minor Hyperlipidaemia

Isa Naina Mohamed

NCT03718286 COMPLETED

Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI

Population Health Research Institute

NCT01751984 COMPLETED

A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance

Esperion Therapeutics, Inc.

NCT03847974 COMPLETED

Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

LIB Therapeutics LLC

NCT03110848 COMPLETED

Effects of Atorvastatin in Graves' Orbitopathy (GO)

University of Pisa

NCT02278471 COMPLETED

The SCCS Polypill Pilot Trial

Vanderbilt University

NCT02927184 COMPLETED

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

Viking Therapeutics, Inc.

NCT01262638 COMPLETED

A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

Esperion Therapeutics, Inc.

NCT01576484 COMPLETED

Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Regeneron Pharmaceuticals

NCT01604824 COMPLETED

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

Regeneron Pharmaceuticals

NCT02963311 COMPLETED

A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

The Medicines Company

NCT03051100 COMPLETED

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Esperion Therapeutics, Inc.

NCT03193047 COMPLETED

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

Esperion Therapeutics, Inc.

NCT00666172 COMPLETED

Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women

National Heart, Lung, and Blood Institute (NHLBI)

NCT02265952 COMPLETED

Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Regeneron Pharmaceuticals

NCT03401580 WITHDRAWN

Efficacy of Fixed-doses of Antihypertensive and Statin Drugs

EMS

NCT01890967 COMPLETED

A Study of LY3015014 in Participants With High Cholesterol

Eli Lilly and Company

NCT02597127 COMPLETED

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

The Medicines Company

NCT02659397 COMPLETED

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

Esperion Therapeutics, Inc.

NCT01941836 COMPLETED

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

Esperion Therapeutics, Inc.

NCT02072161 COMPLETED

Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

Esperion Therapeutics, Inc.

NCT01779453 COMPLETED

A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia

Esperion Therapeutics, Inc.

NCT01607294 COMPLETED

A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

Esperion Therapeutics, Inc.

NCT02775448 TERMINATED

Dose-response Study of Carduus Marianus in Centesimal Scale for Dyslipidemia in Climacteric Overweighed or Obese Women.

Hospital Nacional Homeopático, Mexico

NCT02055976 COMPLETED

Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

Pfizer

NCT00687271 COMPLETED

A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)

Merck Sharp & Dohme LLC

NCT03455777 WITHDRAWN

Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

Akcea Therapeutics

NCT01652703 COMPLETED

A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects

Amgen

NCT00941603 COMPLETED

Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

Merck Sharp & Dohme LLC

NCT02989753 COMPLETED

Effects of Two Herbal Dietary Supplements on Lipid Metabolism in Moderate Hypercholesterolemia and Hypertriglyceridemia

Valbiotis

NCT01105975 COMPLETED

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

Eli Lilly and Company

NCT00690443 COMPLETED

Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia

Aegerion Pharmaceuticals, Inc.

NCT01592240 COMPLETED

Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

Pfizer

NCT03216811 COMPLETED

Nutraceutical in Cardiovascular Primary Prevention

University Hospital of Ferrara

NCT01350141 COMPLETED

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

Pfizer

NCT01342211 COMPLETED

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

Pfizer

NCT02608697 COMPLETED

A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia

Catabasis Pharmaceuticals

NCT01531569 COMPLETED

Single Oral Dose of BeneFlax to Healthy Young and Older Adults

University of Saskatchewan

NCT01227330 COMPLETED

Pilot Program to Improve Statin Adherence and Lower Cholesterol in Older Adults

University of Missouri-Columbia

NCT01812707 COMPLETED

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan

Sanofi

NCT00707746 COMPLETED

Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects

Kastle Therapeutics, LLC

NCT01912560 COMPLETED

Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia

Catabasis Pharmaceuticals

NCT00663234 TERMINATED

IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia

International Maternal Pediatric Adolescent AIDS Clinical Trials Group

NCT02472535 COMPLETED

Study to Evaluate the Effects of MBX-8025 in Patients With HoFH

Gilead Sciences

NCT00728910 COMPLETED

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

University of Pennsylvania

NCT02008084 COMPLETED

A Pilot Study to Evaluate the Lipid Effects of TRIA-662

Cortria Corporation

NCT02100839 COMPLETED

Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia

LipimetiX Development, LLC

NCT00847197 COMPLETED

A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)

Merck Sharp & Dohme LLC

NCT01893515 COMPLETED

The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects

Pronova BioPharma

NCT01972178 TERMINATED

Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

Pronova BioPharma

NCT02541201 COMPLETED

The Effect of a Plant Sterols-Enriched Low-Fat Milk on Lipid Profile in Healthy Southern Chinese (COME-PASS)

The University of Hong Kong

NCT01112423 COMPLETED

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

Bristol-Myers Squibb

NCT01288443 COMPLETED

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy

Sanofi

NCT01288469 COMPLETED

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

Sanofi

NCT01266876 COMPLETED

Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia

Regeneron Pharmaceuticals

NCT01412034 COMPLETED

Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects

Cerenis Therapeutics, SA

NCT01863225 TERMINATED

Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia

Resverlogix Corp

NCT00977288 COMPLETED

A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

Merck Sharp & Dohme LLC

NCT02409537 COMPLETED

Effects of Dietary Antioxidants to Prevent Cardiovascular Disease

Aeromedical Center, Thessaloniki

NCT02087917 COMPLETED

A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia

Zhejiang Hisun Pharmaceutical Co. Ltd.

NCT01332747 COMPLETED

Clinical Study to Evaluate Antihyperlipidemic Effect of a Classical Unani Antiobesity Formulation

Jamia Hamdard University

NCT01970215 COMPLETED

TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)

Xention Ltd

NCT02216825 COMPLETED

Effect of L. Reuteri NCIMB 30242 on Plasma Bile Acid Profile

Micropharma Limited

NCT01327014 COMPLETED

Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia

Beijing Peking University WBL Biotech Co., Ltd.

NCT01630668 COMPLETED

Efficacy of a One-a-Day L. Reuteri NCIMB 30242 Probiotic Supplement Capsule

Micropharma Limited

NCT01077479 COMPLETED

Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome

Western Sydney Local Health District

NCT01388816 COMPLETED

A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels

Dr. Reddy's Laboratories Limited

NCT00690937 COMPLETED

A Multicenter, Active and Placebo-controlled Study of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesteremia

Genzyme, a Sanofi Company

NCT01515241 COMPLETED

Exploratory Study of Plaque Regression

Cerenis Therapeutics, SA

NCT02048410 COMPLETED

Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia

Federico II University

NCT01211847 COMPLETED

Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia

Essentialis, Inc.

NCT01539616 COMPLETED

A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia

Zydus Lifesciences Limited

NCT01423188 COMPLETED

The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation

Resverlogix Corp

NCT01185795 COMPLETED

Efficacy of Cardioviva™ Probiotic Yogurt Formulation

Micropharma Limited

NCT01058083 COMPLETED

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

Bristol-Myers Squibb

NCT01570270 COMPLETED

Cheese Intake and Hypercholesterolemia

Azienda Ospedaliera Brotzu

NCT01531062 COMPLETED

Effect of Nigella Sativa on Lipid Profiles in Elderly

Indonesia University

NCT01279590 COMPLETED

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

Furiex Pharmaceuticals, Inc

NCT01341613 COMPLETED

Efficacy of Cardioviva™ Probiotic Supplement Capsule Formulation

Micropharma Limited

NCT00879112 WITHDRAWN

Study of MB07811 in Subjects With Hypercholesterolemia

Ligand Pharmaceuticals

NCT00981981 COMPLETED

Effect of the Molecular Weight of Oat β-glucan on Its Ability to Lower Serum Cholesterol

Glycemic Index Laboratories, Inc

NCT00673881 COMPLETED

ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study

Radiant Research

NCT00639223 COMPLETED

Safety of Red Yeast Rice for High Cholesterol in Individuals With Statin Intolerance

University of Pennsylvania

NCT01046968 COMPLETED

Lepticore in Metabolic Syndrome and Weight Loss

University of Yaounde 1

NCT00923403 COMPLETED

Efficacy of Sterol-Fortified Low Fat Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans - Study II

University of Manitoba

NCT00677248 COMPLETED

LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe

Karo Bio AB

NCT07581028 NOT YET RECRUITING

Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers

AJU Pharm Co., Ltd.

NCT06980428 RECRUITING

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

AstraZeneca

NCT06451770 RECRUITING

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

Verve Therapeutics, Inc.

NCT07347678 RECRUITING

Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers

Ikaria Bioscience Pty Ltd

NCT07505043 NOT YET RECRUITING

First-in-Human Study of ISH0688: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

SUNHO（China）BioPharmaceutical CO., Ltd.

NCT06164730 RECRUITING

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

Verve Therapeutics, Inc.

NCT07495514 ENROLLING BY INVITATION

A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in Healthy Adult Volunteers

Addpharma Inc.

NCT07491172 RECRUITING

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

CRISPR Therapeutics AG

NCT07428473 NOT YET RECRUITING

A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Monash University

NCT07229118 RECRUITING

A Study to Evaluate COR-1004 in Adult Volunteers.

Corsera Health

NCT07312773 NOT YET RECRUITING

A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C

Addpharma Inc.

NCT07152873 NOT YET RECRUITING

A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A

Addpharma Inc.

NCT07162441 RECRUITING

A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers

Korea United Pharm. Inc.

NCT07074236 NOT YET RECRUITING

Pharmacokinetics and Pharmacodynamics Study

Qilu Pharmaceutical Co., Ltd.

NCT06837077 ACTIVE NOT RECRUITING

Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers

Jiangsu HengRui Medicine Co., Ltd.

NCT06933459 ACTIVE NOT RECRUITING

To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C714 and C714R in Healthy Adults

AJU Pharm Co., Ltd.

NCT07001787 NOT YET RECRUITING

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10510 in Healthy Subjects

Jiangsu Hansoh Pharmaceutical Co., Ltd.

NCT06976489 NOT YET RECRUITING

The Food Effect on PK Characteristics and Safety Profiles of PA-111

Addpharma Inc.

NCT06932705 RECRUITING

A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A

Addpharma Inc.

NCT06504043 ENROLLING BY INVITATION

A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants

Hasten Biopharmaceutical Co., Ltd.

NCT06669429 RECRUITING

A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RS-C1001 Tablets in Chinese Healthy Subjects

Peking University First Hospital

NCT05043181 NOT YET RECRUITING

Exosome-based Nanoplatform for Ldlr mRNA Delivery in FH

Tang-Du Hospital

NCT07590167 NOT YET RECRUITING

A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C

Addpharma Inc.

NCT06732154 COMPLETED

A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects

Fujian Shengdi Pharmaceutical Co., Ltd.

NCT06784349 COMPLETED

ALN-APOC3 in Adult Participants With Dyslipidemia

Regeneron Pharmaceuticals

NCT07412080 COMPLETED

EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia

Eddingpharm (Zhuhai) Co., Ltd.

NCT07097831 COMPLETED

A Clinical Trial of HRS-1301 on the Pharmacokinetics of Rosuvastatin Calcium Tablets in Healthy Subjects

Shandong Suncadia Medicine Co., Ltd.

NCT07319559 COMPLETED

Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on DW5124 in Healthy Adult Volunteers

Daewon Pharmaceutical Co., Ltd.

NCT03747224 COMPLETED

Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients

Arrowhead Pharmaceuticals

NCT06857253 COMPLETED

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1301 in Healthy Subjects

Shandong Suncadia Medicine Co., Ltd.

NCT06742853 COMPLETED

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

AstraZeneca

NCT06541457 COMPLETED

A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects

Fujian Shengdi Pharmaceutical Co., Ltd.

NCT06889012 COMPLETED

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers

Boryung Pharmaceutical Co., Ltd

NCT05851066 COMPLETED

A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers

Visirna Therapeutics HK Limited

NCT01764178 COMPLETED

To Evaluate the Safety and PK Characteristics in Healthy Volunteers-Livalozet

JW Pharmaceutical

NCT04640012 COMPLETED

Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects

Guangzhou JOYO Pharma Co., Ltd

NCT06931327 COMPLETED

To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults

AJU Pharm Co., Ltd.

NCT06758661 COMPLETED

Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers

Chong Kun Dang Pharmaceutical

NCT05398029 COMPLETED

A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease

Verve Therapeutics, Inc.

NCT05787002 COMPLETED

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

AstraZeneca

NCT04774003 COMPLETED

Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C

Novartis Pharmaceuticals

NCT06655311 COMPLETED

A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)

Merck Sharp & Dohme LLC

NCT04692025 COMPLETED

Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers

Gannex Pharma Co., Ltd.

NCT04686994 COMPLETED

Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects

Gannex Pharma Co., Ltd.

NCT06592339 COMPLETED

A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)

Merck Sharp & Dohme LLC

NCT05384262 COMPLETED

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects

AstraZeneca

NCT06475872 COMPLETED

Study to Evaluate the Bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" and "Crestor Tablet 5 mg (Rosuvastatin Calcium)" in Healthy Adult Subjects

Hanlim Pharm. Co., Ltd.

NCT06184269 COMPLETED

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B"

Boryung Pharmaceutical Co., Ltd

NCT04660370 COMPLETED

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348

Chong Kun Dang Pharmaceutical

NCT05749861 COMPLETED

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)

Chong Kun Dang Pharmaceutical

NCT04883658 COMPLETED

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2)

Chong Kun Dang Pharmaceutical

NCT05698043 COMPLETED

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg

Chong Kun Dang Pharmaceutical

NCT05549401 COMPLETED

Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348

Chong Kun Dang Pharmaceutical

NCT05335044 COMPLETED

Study to Evaluate the Safety and Pharmacokinetics of CKD-331

Chong Kun Dang Pharmaceutical

NCT05192356 COMPLETED

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)

Chong Kun Dang Pharmaceutical

NCT05460364 COMPLETED

A Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult Subjects

Boryung Pharmaceutical Co., Ltd

NCT05552495 COMPLETED

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions

Chong Kun Dang Pharmaceutical

NCT05370950 COMPLETED

Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers

Jiangsu HengRui Medicine Co., Ltd.

NCT02275156 COMPLETED

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

Amgen

NCT05245084 COMPLETED

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg

Chong Kun Dang Pharmaceutical

NCT04927221 COMPLETED

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability of DC371739 Treatment in Hypercholesterolemic

Guangzhou JOYO Pharma Co., Ltd

NCT01236430 COMPLETED

A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)

Organon and Co

NCT04987970 COMPLETED

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg

Chong Kun Dang Pharmaceutical

NCT04694989 COMPLETED

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)

Chong Kun Dang Pharmaceutical

NCT04673864 COMPLETED

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386

Chong Kun Dang Pharmaceutical

NCT04155645 COMPLETED

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

AstraZeneca

NCT01377064 COMPLETED

Home-based Exercise for Management of HIV-associated Cardiovascular Disease Risk

University of South Carolina

NCT00739999 COMPLETED

8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

NCT00758004 COMPLETED

Bioequivalence Study Of Pediatric Appropriate Formulation

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

NCT00777517 COMPLETED

Bioequivalence Study On Pediatric Appropriate Formulation

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

NCT04587206 COMPLETED

A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348

Chong Kun Dang Pharmaceutical

NCT02374047 COMPLETED

A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects

Catabasis Pharmaceuticals

NCT03593785 COMPLETED

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

AstraZeneca

NCT01487460 COMPLETED

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

Novartis Pharmaceuticals

NCT03366688 COMPLETED

Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

Innovent Biologics (Suzhou) Co. Ltd.

NCT01859455 COMPLETED

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

Novartis Pharmaceuticals

NCT04055168 TERMINATED

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects

AstraZeneca

NCT02709850 COMPLETED

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia

Ionis Pharmaceuticals, Inc.

NCT03427710 COMPLETED

A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level

Civi Biopharma, Inc.

NCT01695954 COMPLETED

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz

NYU Langone Health

NCT01984073 COMPLETED

Effects of Niacin On Fatty Acid Trapping

University of Pennsylvania

NCT04197817 COMPLETED

A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

Shanghai Junshi Bioscience Co., Ltd.

NCT03707899 COMPLETED

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers Volunteers

Jeil Pharmaceutical Co., Ltd.

NCT02043301 COMPLETED

Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

Pfizer

NCT01426412 COMPLETED

A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol

Eli Lilly and Company

NCT01105598 COMPLETED

A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

Esperion Therapeutics, Inc.

NCT01671085 COMPLETED

A Study of LY3015014 in Healthy Participants With High Cholesterol

Eli Lilly and Company

NCT02044627 COMPLETED

Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002

Esperion Therapeutics, Inc.

NCT02364258 COMPLETED

Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients

Children's Mercy Hospital Kansas City

NCT01243151 COMPLETED

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

Pfizer

NCT03116516 COMPLETED

Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin

Yuhan Corporation

NCT01720537 COMPLETED

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

Pfizer

NCT01133522 COMPLETED

Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin

Amgen

NCT02168803 COMPLETED

A Study of Evacetrapib in Participants With Abnormal Cholesterol

Eli Lilly and Company

NCT02654899 TERMINATED

Single Dose Study of PF-06815345 in Healthy Subjects

Pfizer

NCT03657472 COMPLETED

Bioequivalence Study of CJ-30061 in Healthy Male Volunteers

HK inno.N Corporation

NCT01845428 COMPLETED

Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome

University of North Carolina, Chapel Hill

NCT03545438 COMPLETED

Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003

LIB Therapeutics LLC

NCT01435382 COMPLETED

A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

Pfizer

NCT02065024 COMPLETED

Food Matrix and Genetic Variability as Determinants of Bioavailability and Biological Effects of Beta-cryptoxanthin and Phytosterols

Puerta de Hierro University Hospital

NCT02186483 COMPLETED

Clinical Trial to Investigate the Pharmacokinetics Drug Interaction Between Metformin and Rosuvastatin

Jeil Pharmaceutical Co., Ltd.

NCT02449187 COMPLETED

Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers

Jeil Pharmaceutical Co., Ltd.

NCT02982798 COMPLETED

The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers

Jeil Pharmaceutical Co., Ltd.

NCT03461081 COMPLETED

Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers

Jeil Pharmaceutical Co., Ltd.

NCT01163851 COMPLETED

Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin

Pfizer

NCT02994745 COMPLETED

A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Atorvastatin in Healthy Male Volunteers.

Boryung Pharmaceutical Co., Ltd

NCT03247140 COMPLETED

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers

Jeil Pharmaceutical Co., Ltd.

NCT02979015 COMPLETED

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects

Sanofi

NCT03235362 COMPLETED

A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706

Yuhan Corporation

NCT02508896 COMPLETED

Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects

Affiris AG

NCT02995720 COMPLETED

A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin

Boryung Pharmaceutical Co., Ltd

NCT02066207 COMPLETED

CKD-337 Drug Interaction Study

Chong Kun Dang Pharmaceutical

NCT02753504 COMPLETED

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

Chong Kun Dang Pharmaceutical

NCT03210649 COMPLETED

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

Chong Kun Dang Pharmaceutical

NCT01959971 COMPLETED

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

Sanofi

NCT02951962 COMPLETED

A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin

Yuhan Corporation

NCT02608242 TERMINATED

PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin

Yuhan Corporation

NCT02941848 COMPLETED

Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers

Hanmi Pharmaceutical Company Limited

NCT02667223 TERMINATED

Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase

Pfizer

NCT02933658 COMPLETED

Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers

Daewon Pharmaceutical Co., Ltd.

NCT02408055 COMPLETED

ADME Study in Healthy Male Subjects With TA-8995

Xention Ltd

NCT01723735 COMPLETED

Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects

Sanofi

NCT01448317 COMPLETED

Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers

Sanofi

NCT02651753 COMPLETED

A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337

Chong Kun Dang Pharmaceutical

NCT02387619 COMPLETED

The Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine

Jeil Pharmaceutical Co., Ltd.

NCT01603758 COMPLETED

Physiological Study of Human Cholesterol Metabolism and Excretion

Richard E. Ostlund Jr., MD

NCT02029625 COMPLETED

Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe

NVP Healthcare

NCT02566187 COMPLETED

A Study to Compare the Pharmacokinetics of Fimasartan/Atorvastatin Combination Tablet

Boryung Pharmaceutical Co., Ltd

NCT02569814 COMPLETED

A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin

Boryung Pharmaceutical Co., Ltd

NCT02676830 COMPLETED

Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312

Kowa Research Institute, Inc.

NCT02676596 COMPLETED

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects

Kowa Research Institute, Inc.

NCT02623868 COMPLETED

Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.

Chong Kun Dang Pharmaceutical

NCT02634034 COMPLETED

A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult Volunteers

Kowa Research Institute, Inc.

NCT02314442 COMPLETED

A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Alnylam Pharmaceuticals

NCT02484482 COMPLETED

Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI)

Chong Kun Dang Pharmaceutical

NCT01583647 TERMINATED

A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)

Merck Sharp & Dohme LLC

NCT01012219 COMPLETED

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

Merck Sharp & Dohme LLC

NCT01114490 COMPLETED

Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)

Merck Sharp & Dohme LLC

NCT01071291 COMPLETED

Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)

Merck Sharp & Dohme LLC

NCT00935259 COMPLETED

Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED)

Merck Sharp & Dohme LLC

NCT02156544 COMPLETED

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

Chong Kun Dang Pharmaceutical

NCT01122667 COMPLETED

Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)

Merck Sharp & Dohme LLC

NCT01104519 COMPLETED

A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)

Merck Sharp & Dohme LLC

NCT00990808 COMPLETED

The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

Merck Sharp & Dohme LLC

NCT01163838 WITHDRAWN

Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia

Pfizer

NCT01274104 WITHDRAWN

A Pilot Study on the Effect of Vitamin D Treatment in Patients With Statin-Associated Myalgia

Avera McKennan Hospital & University Health Center

NCT02073084 COMPLETED

A Thorough Corrected QT Interval Trial

Kowa Research Institute, Inc.

NCT01161082 COMPLETED

Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin

Regeneron Pharmaceuticals

NCT01894217 COMPLETED

Statin Therapy to Improve Medication Adherence

Duke University

NCT02047175 COMPLETED

CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)

Chong Kun Dang Pharmaceutical

NCT01493752 COMPLETED

Investigation of the Effect of Dietary Nitrate Treatment on Endothelial Function and Platelet Reactivity in Hypercholesterolemics.

Queen Mary University of London

NCT01308710 COMPLETED

The Effects of a Mediterranean Diet in Pediatric Hyperlipidemia

University of California, San Francisco

NCT01979601 COMPLETED

Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia

Novartis Pharmaceuticals

NCT01975961 COMPLETED

PK Study of Telmisartan/Rosuvastatin FDC Compared to Combination of Telmisartan and Rosuvastatin

Yuhan Corporation

NCT01785329 COMPLETED

Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects

Sanofi

NCT01918709 COMPLETED

Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers

LG Life Sciences

NCT01918358 COMPLETED

Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg

LG Life Sciences

NCT01651273 TERMINATED

A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia

Bristol-Myers Squibb

NCT01842256 COMPLETED

Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.

Chong Kun Dang Pharmaceutical

NCT01842230 COMPLETED

Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine

Chong Kun Dang Pharmaceutical

NCT01725594 COMPLETED

A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003

Catabasis Pharmaceuticals

NCT01670734 COMPLETED

Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects

Sanofi

NCT01443650 COMPLETED

Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects

Sanofi

NCT01448304 COMPLETED

Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)

Sanofi

NCT01448239 COMPLETED

Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)

Sanofi

NCT01879020 COMPLETED

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects

Tanabe Pharma Corporation

NCT01878474 COMPLETED

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects

Tanabe Pharma Corporation

NCT01806324 COMPLETED

A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects

HanAll BioPharma Co., Ltd.

NCT01761955 COMPLETED

Metabolic Health Benefits of Dairy Protein

University of Manitoba

NCT01406431 COMPLETED

Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects

JW Pharmaceutical

NCT01353404 COMPLETED

Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)

Samyang Biopharmaceuticals Corporation

NCT01474161 COMPLETED

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

Genfit

NCT00585143 COMPLETED

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

AstraZeneca

NCT01609907 COMPLETED

Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan

Yuhan Corporation

NCT00966225 COMPLETED

LIP-01 in Hypercholesterolemia

Afexa Life Sciences Inc

NCT01365663 COMPLETED

Multiple Ascending Dose Study of SPC4955 in Healthy Subjects

Santaris Pharma A/S

NCT01350960 TERMINATED

Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH

Santaris Pharma A/S

NCT00979368 COMPLETED

Safety Study of BMS-816336 in Healthy Male Subjects

Bristol-Myers Squibb

NCT01082562 TERMINATED

Safety Study of BMS-844421 for Treatment of Hypercholesterolemia

Bristol-Myers Squibb

NCT00927459 TERMINATED

Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

Arbutus Biopharma Corporation

NCT07581808 NOT YET RECRUITING

Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention

University Medical Centre Ljubljana

NCT05365425 RECRUITING

Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

Seoul National University Bundang Hospital

NCT07508254 NOT YET RECRUITING

Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome

Punjab Institute of Cardology

NCT07442630 ACTIVE NOT RECRUITING

Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides

JW Pharmaceutical

NCT07314775 NOT YET RECRUITING

Yangxin Dawayimixike Honey Paste for Carotid Atherosclerotic Plaque With Dyslipidemia: A Randomized Controlled Clinical Study

Xinjiang Uygur Pharmaceutical Co., Ltd.

NCT07255820 NOT YET RECRUITING

Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol

Bahria University

NCT06789432 RECRUITING

Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population

Dr. Md. Alimur Reza

NCT06784557 RECRUITING

Effect of Ezetimibe on Gut Microbiota

Yonsei University

NCT06586684 NOT YET RECRUITING

Effect of Small Interfering RNA Inclisiran on Carotid Plaques As Assessed by Carotid Ultrasound

First Affiliated Hospital of Xinjiang Medical University

NCT06386419 COMPLETED

A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Novartis Pharmaceuticals

NCT05192941 COMPLETED

Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

Novartis Pharmaceuticals

NCT01212159 COMPLETED

Telephone Based Management of Hyperlipidemia

Temple University

NCT06431763 COMPLETED

A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

Novartis Pharmaceuticals

NCT06925100 COMPLETED

A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan

Daiichi Sankyo

NCT02098460 COMPLETED

To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject

Otsuka Beijing Research Institute

NCT04638400 TERMINATED

Anti-inflammatory Effects of Simvastatin

paresh Dandona

NCT01422421 COMPLETED

Intensive Blood Pressure and LDL Lowering in Diabetic Patients With Coronary Artery Disease

Takeshi Morimoto

NCT00746811 COMPLETED

Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia

Provident Clinical Research

NCT03403374 COMPLETED

Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia

Amgen

NCT01611883 COMPLETED

A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)

Organon and Co

NCT00871351 COMPLETED

Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)

Organon and Co

NCT06359353 COMPLETED

Effect of Pitavastatin on Bone

Seoul National University Bundang Hospital

NCT06231459 COMPLETED

Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

NCT03615534 COMPLETED

Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females

Lewai Sharki Abdulaziz, MSc PhD

NCT04510844 WITHDRAWN

Evolocumab In Advanced Chronic Kidney Disease Trial

NYU Langone Health

NCT05467384 COMPLETED

Effect of Amlodipine on the Lipid Profile of Newly Diagnosed Hypertensive Patients

Ayub Teaching Hospital

NCT05465278 COMPLETED

Alirocumab and Plaque Burden In Familial Hypercholesterolaemia

Fundación Hipercolesterolemia Familiar

NCT03847506 COMPLETED

Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets

HK inno.N Corporation

NCT01166633 COMPLETED

Efficacy and Safety Study of Pitavastatin Versus Atorvastatin to Treat Hypercholesterolemia

JW Pharmaceutical

NCT01587235 WITHDRAWN

A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)

Organon and Co

NCT03550287 COMPLETED

Evaluation of the Effect of a Shiitake Extract on Lipid Profile in Subjects With Moderate Hyperlipidemia

Instituto de Investigación Hospital Universitario La Paz

NCT03694197 TERMINATED

Long Term Safety Study of PRALUENT

Regeneron Pharmaceuticals

NCT02342015 COMPLETED

Effect of Atorvastatin on Bone-vascular Axis

University of Padova

NCT02957682 COMPLETED

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Regeneron Pharmaceuticals

NCT03267329 COMPLETED

Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension

Yuhan Corporation

NCT02437084 COMPLETED

Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling

Stanford University

NCT03331666 TERMINATED

Impact of LDL-cholesterol Lowering on Platelet Activation

Columbia University

NCT00917579 COMPLETED

Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

NCT00844376 COMPLETED

Bioavailability Study for New Atorvastatin Formulation

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

NCT00917644 COMPLETED

Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

NCT00708370 COMPLETED

A Study to Evaluate the Efficacy of a Counselling and Advisory Care for Health (COACH) Program in Dyslipidemic Patients.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

NCT02772640 COMPLETED

Effectiveness of Treatment of Hypercholesterolemia With Rosuvastatin and Ezetimibe

Collegium Medicum w Bydgoszczy

NCT01190007 COMPLETED

Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

NCT01054508 COMPLETED

Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers

Manchester University NHS Foundation Trust

NCT04511000 COMPLETED

Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg

Chong Kun Dang Pharmaceutical

NCT03074630 COMPLETED

Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)

Amsterdam UMC, location VUmc

NCT03559309 TERMINATED

Investigating the Effects of Lipid-therapy Intensification With Alirocumab on Endothelial Function, Carotid Arteries, Lipoprotein Particle Subfractions, Inflammation and Post-prandial Lipemia

Medical University of Graz

NCT01729156 COMPLETED

Effects of Metformin on Hepatic FFA Metabolism

Lars Christian Gormsen

NCT03217409 COMPLETED

A Study to Compare Rosuvastatin/Ezetimibe and Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia

Yuhan Corporation

NCT00889226 COMPLETED

Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia

JW Pharmaceutical

NCT02984982 COMPLETED

Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia

Sanofi

NCT02938949 COMPLETED

Alirocumab in Patients With Acute Myocardial Infarction

Virginia Commonwealth University

NCT03604471 COMPLETED

Lipid-lowering Therapy Individualization

Université Catholique de Louvain

NCT03446261 COMPLETED

Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia

Yuhan Corporation

NCT03949374 COMPLETED

Clinical Trial to Evaluate Efficacy and Safety of ROVASRO 10mg Versus CRESTOR 10mg in Hypercholesterolemic Patients

Yonsei University

NCT02824432 COMPLETED

Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation

Takeda

NCT02839902 COMPLETED

Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood

Takeda

NCT01212900 COMPLETED

Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression

National Heart, Lung, and Blood Institute (NHLBI)

NCT02499185 TERMINATED

Study Evaluating Novel Biomarkers of AKI (Acute Kidney Injury) in Post-operative Patients

Universitair Ziekenhuis Brussel

NCT02642159 COMPLETED

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Sanofi

NCT03470376 COMPLETED

NUtraceutical TReatment for hYpercholesterolemia in HIV-infected Patients

University Of Perugia

NCT00833976 COMPLETED

Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia

Massachusetts General Hospital

NCT01131832 COMPLETED

Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols

University of Manitoba

NCT01660191 COMPLETED

A Study Comparing CoQ10 Levels While Taking 3 Different Statins

University of Kansas Medical Center

NCT01052311 TERMINATED

The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients

Sheba Medical Center

NCT02442700 COMPLETED

Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir

Ramathibodi Hospital

NCT02913170 COMPLETED

Nattokinase Supplementation and Hemostatic Factors

Yonsei University

NCT02644109 COMPLETED

Effect On Serum Cholesterol Of Dairy Products With Addition Of Esterified Phytosterols

University of Chile

NCT01025492 TERMINATED

Study of Trilipix Effects on Lipids and Arteries

University of Utah

NCT02103049 COMPLETED

The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients

University Medical Centre Ljubljana

NCT02280590 COMPLETED

Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia

Dong-A ST Co., Ltd.

NCT02422927 COMPLETED

Nutraceutical Combination in Patients With Low-grade Systemic Inflammation

University Of Perugia

NCT01043380 COMPLETED

Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound

Kumamoto University

NCT00738985 WITHDRAWN

Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

NCT01666067 COMPLETED

Vascular and Metabolic Effects of Vytorin vs Simvastatin

Gachon University Gil Medical Center

NCT01660919 COMPLETED

Vascular and Metabolic Effects of Rosuvastatin

Gachon University Gil Medical Center

NCT01660945 COMPLETED

Vascular and Metabolic Effects of Vytorin

Gachon University Gil Medical Center

NCT00700037 COMPLETED

Change in Plaque Characteristics With Atorvastatin

Wakayama Medical University

NCT01409434 COMPLETED

Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study

University of Florida

NCT01448174 COMPLETED

Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients

Poznan University of Medical Sciences

NCT02133534 TERMINATED

The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease

Duke University

NCT01458977 COMPLETED

Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

NCT02153879 COMPLETED

Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment

Institut Investigacio Sanitaria Pere Virgili

NCT00630734 COMPLETED

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin

University of Colorado, Denver

NCT01466608 COMPLETED

Influence of OATP1B1 and BRCP Genotype on Rosuvastatin PK, PD and Lipidomics in Hyperlipidemic Patients

Seoul National University Hospital

NCT01301066 COMPLETED

A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects

Kowa Research Institute, Inc.

NCT00819910 TERMINATED

Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)

Ahmad Slim

NCT02078167 COMPLETED

Long Term Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols and Berberine) in Low-moderate Risk Hypercholesterolemic Patients: a Double-blind, Placebo Controlled Study

Comitato Etico di Area Vasta Sud Est

NCT02057302 COMPLETED

A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia

China Academy of Chinese Medical Sciences

NCT01251991 COMPLETED

Cholesterol Lowering Treatment With Psyllium Husks and Isolated Soy Protein in Hypercholesterolemia

Aalborg University Hospital

NCT01285544 COMPLETED

The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia

Seoul National University Hospital

NCT01624207 COMPLETED

The Efficacy and Safety of Atorva® 20mg Versus Lipitor® 20mg

Seoul National University Hospital

NCT00861861 COMPLETED

Comparison of Pitavastatin With Atorvastatin in Increasing High Density Lipoprotein - Cholesterol (HDL-C) and Adiponectin in Patients With Dyslipidemia and Coronary Artery Disease (CAD)

Kumamoto University

NCT01023607 COMPLETED

Evaluation of Statin-induced Lipid-rich Plaque Progression by Optical Coherence Tomography (OCT) Combined With Intravascular Ultrasound (IVUS)

Harbin Medical University

NCT01600690 COMPLETED

Effects of 5-day Statin Withdrawal on Endothelial Progenitor Cells and Inflammatory Markers in Type 2 Diabetic Patients

University of Padova

NCT00603876 COMPLETED

Efficacy of Almonds Added to Chronic Statin Therapy

University of Kansas

NCT01778244 COMPLETED

Metformin for Treatment of Antipsychotic-induced Dyslipidemia

Central South University

NCT01321034 COMPLETED

Effect of Niacin in the Lipoprotein (a) Concentration

Instituto Aragones de Ciencias de la Salud

NCT01524601 COMPLETED

The Rosuvastatin In TrAnsplant Recipients Study

University of Oslo School of Pharmacy

NCT01004237 COMPLETED

Additive Effects of Pravastatin and Valsartan

Gachon University Gil Medical Center

NCT01029522 COMPLETED

Dyslipidemia in Cardiovascular Disease

Chong Kun Dang Pharmaceutical

NCT01625442 COMPLETED

Crocus Sativus (Saffron) and Berberis Vulgaris (Barberry Fruit) in Metabolic Syndrome

Birjand University of Medical Sciences

NCT00637078 COMPLETED

STITCH2 (Simplified Therapeutic Intervention to Control Hypertension and Hypercholesterolemia)

University of Western Ontario, Canada

NCT01256476 COMPLETED

Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia

Kowa Research Institute, Inc.

NCT00640276 COMPLETED

Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome

JW Pharmaceutical

NCT01239004 COMPLETED

Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

Radiant Research

NCT01089231 COMPLETED

Effects of Omega-3 Fatty Acids on the Human Gene Expression

Gottfried Wilhelm Leibniz Universität Hannover

NCT00932620 COMPLETED

Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL)

University of Ioannina

NCT01414803 COMPLETED

Tolerability and Efficacy of Rosuvastatin - Fenofibrate Combine Therapy in Korean Patients With Combined Hyperlipidemia

Yonsei University

NCT01108978 TERMINATED

Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease

Nang Kuang Pharmaceutical Co., Ltd.

NCT00701727 COMPLETED

Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study

Radiant Research

NCT01081548 COMPLETED

A Clinical Trial Study to Evaluate Efficacy and Safety of Atorvastatin in Korean Patients With Hypercholesterolemia

Yonsei University

NCT00793364 COMPLETED

Effect of Plant Stanol Ester-Containing Spread on Estimated Cardiovascular Risk in Comparison to Mediterranean Diet

Hellenic Atherosclerosis Society

Full Dyslipidemia Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only